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ABSTRACT
Non-tuberculosis  mycobacteria  (NTM),  as  certain  species  of  mycobacteria,  can  affect  human  in  several  ways.  In  the 
preceding years, the rate of NTM detection has risen in both immunocompromised and immunocompetent patients. On the 
other hand, several reports have debated the possibility of co-infection of both Mycobcateriu tuberculosis (MTB) and NTM 
in individuals that puts the role of NTM in disease manifestations under question. Moreover, it is now proven that some of 
the cases that are identified as anti-TB treatment failure or suspected for drug resistance are actually NTM.
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INTRODUCTION
Non-tuberculous mycobacteria, as certain species 
of  mycobacteria,  can  affect  humans  in  several 
ways  (1-3).  Though  they  are  thought  to  affect  the 
immunocompromised patients more frequently, several 
studies  have  demonstrated  NTM  as  the  etiological 
agent of disease  in immunocompetent hosts (4-6).
In the past few years,  rate of NTM detection has risen 
in both immunocompromised and immunocompetent 
patients. This may be partly attributed  to  advances 
in  mycobacteriologic  detection  methods,  increase 
in  acquired  immunodeficiency  cases  (either  HIV 
infection or use of immunosuppressive drugs), or just 
simply actual increase in NTM infection itself (1).
On the other hand, several reports have debated 
the possibility of co-infection of both MTB and NTM 
in an individual that puts the role of NTM in disease 
manifestations under question. Moreover, it has now 
been proven that some cases that are identified as anti-
TB treatment failure or suspected for drug resistance 
are actually NTM (1).
A broad spectrum of non-tuberculous mycobacteria 
live  freely  in  our  surrounding  environment  (1-3). 
However, they may cause disease in both human or 
animals. Human to human transmission of NTM has 
not yet been confirmed. Though, animal to human 
transmission has been suggested in some reports (7-8). 
So, role of NTM, particulalry when public health issues 
are concerned, should be emphasized despite the fact 
that no definitive route of transmission is yet proposed 
(i.e., either human to human or animal to human).
NTM and the diseases they cause have received 
much attentions world-wide during the past decade. 
Also, with regard to the enormity of varieties of these 
organisms, the sporadic diseases caused by them, and 
the difficulties in detecting such bacilli, the reported 
cases are still somewhat few. Therefore, any kind of 
disease caused by NTM, especially those presenting 
with clinical manifestations during their involvement 
and rare cases would merit being reported for further 
considerations.
Mycobacterium lentiflavum was first identified in 
1996 as a disticnt strain (9). Since then, several cases 
of infections with this bacilli have been reported  with 
skin or lymph node involvement. Also, it has been 
isolated from pleural effusions, ascites, and from lung 
tissues (10-12).
This paper is the first report of documented M. 
lentiflavum infection from Iran. 
Case Report
A 44 year-old Iranian woman who was resident of   
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Kurdestan  province in the west of Iran, presented to 
our center with cough, scanty sputum, left unilateral 
pleuritic  chest  pain,  anorexia  and  weight  loss  for 
the  last  three  months  that  had  exacerbated  in  the 
preceding couple weeks. 
In  1999,  her  symptoms  first  started  and  thus 
she underwent an assessement for TB. The clinical 
manifestations  typical  for  and  the  radiological 
findings  consistent  with  TB,  accompanied  with 
positive sputum smear for Acid Fast Bacilli, led to the 
initiation of anti-TB treatment. She had received the 
WHO CAT Ι regimen for six months at a peripheral 
health care center in Iran. Since then, the patient has 
been treated with  anti-TB medication three times, 
including  CAT  ΙΙ  regimen,  due  to  recurrence  of   
clinical manifestations and each time the treatment 
course was completed and cure was documented by 
obtaining negative  sputum smear negative for AFB.
For the last three months, and the first time after her 
third  treatment  regimen,  her  symptoms  re-emerged. 
She  was evaluated at the peripheral health care center 
and due to a positive smear for AFB , was referred to 
our center as a suspected case for MDR-TB. 
At admission, she appeared quite cachectic. There 
was no cervical or axillary lymphadenopathy. In chest 
auscultation, inspiratory crackles were  detected mainly 
on the left middle and lower regions. Tuberculin skin 
test (TST) performed with PPD revealed 10 mm of 
induration. No BCG vaccination scar was detected. 
As a suspected MDR-TB case and according to our 
routine protocol for these patients, mycobacteriologic 
studies (including sputum smears and cultures, and 
Drug  Suscpetibility  Testing  (DST)),  polymerase 
chain reaction (PCR) specific for MTB , and other 
identification  tests  were  requested.  The  sputum 
smears rendered a 2+ result.
The patient, as a suspected MDR-TB case, underwent     
the  standardized  anti-TB  regimen  consisting  of 
cycloserine, ofloxacin, prothionamide, and amikacin.
The anti-HIV antibody test was negative. Sputum 
smear  was  2+  for AFB.  Chest  X-ray  showed  bilateral 
fibrocavitary  destructive  changes  and  biapical  pleural 
thickening  Chest  CT  scan  revealed  fibrocavitary 
destructive  change  in  both  upper  lobes,  heart  and 
mediastane shift toward left side, biapical pleural thickening 
and loss of volume seen with compensatory over aerated and 
emphysematous  lower lobe  changes (Fig. 1) .
Drug  suscpetibility  testing  (DST)  demonstrated 
resistance  to  all  first  line  anti-TB  drugs.  PCR  for 
MTB was negative and with further evaluations using 
identification methods, Mycobcaterium lentiflavum was 
identified in the specimens.
As Mycobacterium lentiflavum had been isolated, 
the  treatment  regimen  changed  to  clarithromycin, 
Ofloxacin, and amikacin. The sputum culture turned 
negative  after  two  months  of  treatment  and  has 
remained so for the time being while the patient has 
received more than six months medication.  
Specimens obtained from the patient were cultured 
on the Lowenstein – Jensen (L.J.) slants so that 100-
120  colonies  grew.  Whenever  polymerase  chain–
reaction using RFLP-IS6110 probe and spoligotyping 
were  negative,  conventional  biochemical  tests  as 
identification methods (13) were performed for both 
the patient strain as well as standard NTM (obtained 
from  Department  of  Mycobacteriology,  National 
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DISCUSSION
NTM  most commonly presents with pulomonary 
manifestations.  However,  lymph  node,  skin,  soft 
tissue involvement as well as disseminated disease 
are  of  clinical  importance  (1).  Mycobacterium 
lentiflavum was first identified in 1996 as a distinct 
strain. Since then, several cases of infections with this 
bacilli have been reported with skin or lymph node 
involvements.  Also, it has been isolated from pleural 
effusions, ascites, and from lung tissue . 
However,  the  pulmonary  disease  caused  by  M. 
lentiflavum are few. Furthermore, most of the reported 
cases were detected in immunocompromised patients. It 
is of note that this case occurred in an immunocompetent 
patient and there are few such reports available (15) As 
well, after administering the approprite treatment for M. 
lentiflavum, the clinical condition of the patient improved, 
her sputum smears and culture turned negative; therefore, 
this is among few cases that the M. lentiflavum treatment 
outcome is determined.
The notable charcateristics of our case was that 
she  had  the  history  of  several  anti-TB  treatments. 
According  to  NTP,  anti-TB  treatment  is  initiated 
based on positive smears, culture and DST are not 
routinely performed. So, we do not know about the 
type of mycobacterium in her previous illnesses.
Accordingly, in patients who are treated according 
to  NTP  (merely  based  on  positive  smears),  NTM 
should  be  kept  in  mind  especially  if  the  patient 
does not properly respond to the standard anti-TB 
regimens. Moreover, despite some recommendations 
for treatment of M. lentiflavum, it seems that further 
evaluations should be developed to find the optimal 
therapeutic  protocol and regimen. 
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